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Abstract 
Objectives: Before an intervention is publicly funded within the UK, the cost-effectiveness is 
assessed by the National Institute of Health and Care Excellence (NICE). The efficacy of an 
intervention across the patients’ lifetime is often influential of the cost-effectiveness analyses, but is 
associated with large uncertainties. We reviewed committee documents containing company 
submissions and evidence review group (ERG) reports to establish the methods used when 
extrapolating survival data, whether these adhered to NICE Technical Support Document (TSD) 14, 
and how uncertainty was addressed. 
Methods: A systematic search was completed on the NHS Evidence Search webpage limited to single 
technology appraisals of cancer interventions published in 2017, with information obtained from the 
NICE website. 
Results: 28 appraisals were identified, covering 22 interventions across 18 diseases. Every economic 
model used parametric curves to model survival. All submissions used goodness-of-fit statistics and 
plausibility of extrapolations when selecting a parametric curve. 25 submissions considered alternate 
parametric curves in scenario analyses. Six submissions reported including the parameters of the 
survival curves in the probabilistic sensitivity analysis. ERGs agreed with the company’s choice of 
parametric curve in nine appraisals, and agreed with all major survival-related assumptions in two 
appraisals. 
Conclusions: TSD 14 on survival extrapolation was followed in all appraisals. Despite this, the choice 
of parametric curve remains subjective. Recent developments in Bayesian approaches to 
extrapolation are not implemented. More precise guidance on the selection of curves and modelling 
of uncertainty may reduce subjectivity, accelerating the appraisal process.  
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1 Introduction 
Globally, health service providers are under pressure to deliver a continuously improving standard of 
care with a finite pool of resources. This results in a desire for funding decision-makers, such as 
National Institute of Health and Care Excellence (NICE) in England, Wales and Northern Ireland, to 
obtain value for money, often setting thresholds where the price the decision-maker is willing to pay 
is based on the efficacy of the drug. This requires a common scale on which all diseases and 
interventions can be contrasted. In the UK, quality-adjusted life years (QALY) are commonly used, 
where patients’ predicted life expectancy is multiplied by a value estimating the quality of their life 
across their lifetime. The resulting cost/QALY is considered alongside other factors, including 
whether an intervention can be considered to meet end-of-life criteria or an unmet need, before a 
decision on whether to reimburse a treatment in the National Health Service. Whilst unit prices are 
often fixed and contain little uncertainty, there is often considerable uncertainty over the clinical 
outcomes, such as life expectancy, and their associated resource use, with observed data often only 
spanning a couple of years. Commonly, progression-free survival (PFS) and overall survival (OS) data 
are modelled parametrically, with curves extrapolated across the patients’ lifetime time horizon. The 
choice of parametric curves is often one of the most influential factors of a cost-effectiveness model, 
with subtle differences between parametric fits over a short follow-up period often yielding large 
disagreement upon extrapolation. Survival related assumptions often influence the manufacturers 
discount on the list price (e.g. through a commercial access agreement or patient access scheme) to 
ensure that the cost-effectiveness results fall within the thresholds NICE considers to be cost-
effective. OS extrapolation is often more influential on a cost-effectiveness analysis, as PFS data are 
more mature with the PFS extrapolations containing less uncertainty. The NICE Decision Support 
Unit (DSU) has published Technical Support Document (TSD) 14 which suggests methods on how to 
assess the suitability of a survival model [1], though it remains unclear how closely this is adhered to. 
One of NICE’s types of appraisal is the single technology appraisal (STA), where a single intervention 
is assessed for a single indication. The manufacturer is invited to submit evidence to support the 
decision making process. This evidence is assessed by an interdisciplinary evidence review group 
(ERG), who produce an independent and unbiased report of the evidence that is presented alongside 
the manufacturer submission to a NICE appraisal committee. The committee then decide whether to 
fund the intervention, based on the clinical and cost-effectiveness evidence. Further information on 
the single technology process can be found on the NICE website [2].  
This paper presents a review of STAs of cancer treatments whose guidance was published by NICE in 
2017, focusing on the approaches to the extrapolation of survival data. It set out to achieve the 
following aims: 
 Identify methods used by companies in their approaches to survival extrapolation, and 
investigate whether these adhere to NICE guidance  
 Identify whether the methods used by company’s result in robust selection of extrapolation  
and investigate how uncertainty in extrapolations is accounted for 
To achieve these aims, we focused on appraisals of interventions targeting cancers to ensure 
relevant survival information would be present. We limited the search to STAs to maximise 
consistency in reporting standards.  
1.1 Summary of NICE TSD 14 on Survival Extrapolation 
NICE TSD 14 [1] is a report by NICE’s Decision Support Unit, providing guidance on survival analysis 
and extrapolation of survival data within economic evaluations. Section 3 of TSD 14 lists some 
suggested methods for assessing the suitability of survival models. These are: 
Visual Inspection: Comparing the parametric models to the observed Kaplan-Meier data. 
Log-Cumulative Hazard Plots: TSD 14 suggests plotting the observed log-cumulative hazard data, 
usually against log-time, to assess the behaviour of the hazard from the observed data, which can 
assess the suitability of the exponential or Weibull functions. The Log-Cumulative hazard plot can 
also be used to assess the hazard proportionality of different treatment arms, helping to decide 
whether an assumption of proportionality should be maintained in the extrapolation. Other plots 
such as Quantile-Quantile (QQ) and graphs of residuals (e.g. Martingale, Schoenfeld) can also be 
considered. 
Information Criterion: The most commonly used information criteria are the Akaike information 
criterion (AIC) and Bayesian information criterion (BIC). These both allow a comparison of non-
nested models, which is necessary due to the differing functional forms of the different parametric 
models.  
Clinical validity and External Data: Comparison of extrapolations of parametric models to predictions 
made by expert clinical opinion and to data with longer follow-up of similar patients and treatments, 
typically from other trials or registry databases. 
Unless separate forms are strongly justified with clinical expert opinion, biological plausibility and 
robust statistical analysis, the TSD recommends using the same parametric form for both the 
intervention and the comparator. An example of an appraisal where separate forms may have been 
appropriate was TA519 where pembrolizumab (an immunotherapy) was compared to 
chemotherapies in patients with urothelial cancer [3]. 
2 Methods 
2.1 Study Eligibility Criteria 
For inclusion in this review, only single technology appraisals of interventions for cancerous diseases 
published in 2017 were targeted.  
2.1 Search Strategy 
A systematic search was completed on the NHS Evidence Search webpage on 16/01/2018, using the 
terms neoplasm* or neoplasia or tumor* or tumour* or cancer* or carcinoma* or malignan* or 
adenocarcinoma* or metasta*, filtered to guidance published by NICE in the area of Drugs and 
Technologies in 2017. A broader search of additional electronic databases was not required due to 
the particular focus of this review.  
2.2 Search Selection 
PA and DG independently assessed whether the studies met the inclusion criteria initially at title and 
abstract, and then at full text, with any disagreements resolved through discussion or recourse to a 
third reviewer (MC). 
2.3 Data Extraction  
Information from each appraisal were collected from the initial set of relevant committee papers 
into a data extraction form (available on request), performed by DG. Median and maximum follow-
up durations were extracted from text where available, or from Kaplan-Meier plots. Where multiple 
trials were considered with a single appraisal, the trial with the longest follow-up was used for this 
analysis. 
2.4 Quality Assessment 
As all appraisals are scrutinised by an ERG and NICE technical team, it was not necessary to use 
further quality assessment tools.  
 
3 Results 
Figure 1 shows the outcomes of the search and screening process, including the reasons for 
exclusion, in a Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
diagram [4] . 
The final 28 pieces of guidance covered 22 primary interventions across 16 different diseases. NICE 
recommended funding through the NHS for 18 of the appraisals [5-22], eight were recommended for 
funding through the CDF [23-30] and two were not recommended for funding [31, 32]. 
An overview of appraisals included in this review is presented in Table 1 and a summary of the 
findings is shown in Table 2.  
 Four submissions used a Markov multistate model to assess cost-effectiveness [13, 19, 20, 30], and 
21 used a Partitioned Survival model [5-12, 14, 16-18, 21-28, 31, 32]. It was unclear for two 
submissions which modelling approach was implemented [15, 17], and for a further submission both 
a semi-Markov model and partitioned survival model were presented [29]. 
Every appraisal used frequentist parametric models to extrapolate at least one set of time-to-event 
data. In one appraisal splines were submitted as the company base case [25], however all others 
opted for a standard parametric form, either exponential, Weibull, log-normal, log-logistic, gamma, 
generalised gamma or Gompertz. Piecewise modelling featured in 11 appraisals [5, 6, 8, 10, 12, 14, 
19, 22-25], usually featuring initial KM data being implemented into the economic model, followed 
by a parametric curve after a certain point in time. This approach was more commonly preferred by 
ERGs (8 appraisals) than companies (4 appraisals). Occasionally, a combination of distinct parametric 
curves were used to model the same survival outcome, e.g. when specific groups of patients had 
differing levels of risk, which was more common in the Markov models [7, 12, 15, 20, 29]. In one 
appraisal a company choose to model a survival outcome without extrapolating using a parametric 
form, and instead modelled observed KM data [28], compared with ERGs favouring this approach in 
three appraisals [16, 28, 32]. 
The time horizon of 27 models was reported, ranging from 10 to 100 years, with a mean of 31 years. 
All models used survival data from at least one clinical trial. The length of maximum observed follow-
up periods of the main contributing trials, ranged from 1.4 years to 6.8 years, with a mean of 3.1 
years. The percentage of each model’s time horizon supported by observed data ranged from 5.8% 
to 37.5% with a mean of 12.4%. When the analysis was repeated using only reported median follow-
up, the observed periods ranged from 0.4 years to 5.9 years, mean 2.0 years and corresponding 
observed time horizon percentages ranged from 2.0% to 11.6%, mean 6.5%. 
All submissions reported using goodness of fit statistics (e.g. AIC and BIC) and plausibility of 
predictions when selecting the parametric curve. Eighteen reports also considered visual fit of 
parametric curves to the observed data, predominantly overlaid on a KM plot [8-11, 13, 18-23, 25-
31]. Six submissions compared extrapolations to external sources of data [12, 17, 18, 24, 25, 28]. Five 
presented log-cumulative hazard plots [6, 10, 14, 21, 27], and two considered QQ-plots [6, 21]. Only 
two submissions reported verifying the consistency between PFS and OS curves [15, 26]. All 
appraisals used the same functional form for all modelled comparators. 
Three company submissions did not present cost-effectiveness results for alternative parametric 
curves [5, 10, 14]. Five appraisals reported the inclusion of the survival distribution parameters in 
their probabilistic sensitivity analysis (PSA) [18, 19, 21, 29, 32] although it was common for reports to 
omit the full list of parameters included in the PSA, and it is possible that more PSAs did include 
survival parameters. 
Each submission was critically appraised by an ERG who agreed with the company’s choice of 
parametric fits in nine appraisals [8, 10, 14, 15, 18, 19, 21, 26, 31]. In two appraisals it was unclear 
whether the ERG maintained the company’s choice or chose different curves [9, 16], meaning in 
most appraisals the ERG disagreed with the company’s choice. In terms of broader survival 
assumptions (including choice of parametric curve), in three appraisals the ERG agreed with all major 
assumptions made by the pharmaceutical company [8, 18, 26], and in one of these cases the NICE 
committee preferred different survival assumptions to those agreed by the ERG and company [26]. 
In all other appraisals, the ERG disagreed with at least one major assumption of the survival 
extrapolation, for reasons including the methods used for adjusting for crossover, the consideration 
of internal and external data and the duration of treatment effect.  
4 Discussion 
This review of 28 NICE technology appraisal submissions showed that pharmaceutical companies 
generally take a transparent approach in their modelling and extrapolation of survival data in their 
economic analyses. We found that extrapolation and curve selection were in line with TSD 14, with a 
range of parametric models use to predict future survival. We avoided making inference on the 
specific parametric curves chosen in each appraisal due the wide variety of cancers and 
interventions covered. 
Frequently the reporting of methods of curve selection was not comprehensive with only a couple of 
the recommended methods by NICE TSD 14 presented in a company submission. It was unclear why 
other methods were not presented, perhaps due to their discordance with the presented methods, 
for brevity or the fact that they were never utilised.  
NICE STAs can often go on for many months, requiring multiple committee meetings and generating 
numerous sets of committee documents for a single appraisal. Inconsistency in NICE’s provision of 
these documents meant it was unclear at how many committee meetings an appraisal was 
discussed, and masked the identity of the major points of contention. In addition, key information 
was often redacted, e.g. life-year estimates and resulting ICERs, meaning it was difficult to ascertain 
precisely how influential the survival curves were, and prevented a more quantitative analysis. It was 
also unclear whether the same definition of median follow-up was used across each appraisal [33]. It 
is possible that either the company or ERG changed their position on survival assumptions based on 
additional arguments or data being put forward, which were not captured by this review.  The 
conduct of future reviews would be enhanced with uniformity in the presentation of documentation 
by NICE, and greater consistency across companies in their presentation of survival extrapolation 
and justification.  
The strengths of this review are that it captures the most up-to-date methods to extrapolate from 
survival data, across a wide range of interventions and cancers, as well as the types of economic 
model used. The systematic search identified all relevant appraisals, and summarised their methods 
of extrapolation and assessing uncertainty. 
The limitations of this review are that it covers appraisals from a single year and is specific to cancer. 
This timeframe may mean it has missed other techniques used by companies.   
The findings of this review are generaliseable to other disease areas where extrapolations of time-
to-event outcomes are of primary concern to the decision-maker, particularly where partitioned 
survival models are suitable. They may not be representative of submissions to other decision 
makers who do not base decisions on patient population lifetime horizon.  
One implication of this review is that the current version of TSD 14 may be insufficient in its 
instructions for the extrapolation of survival curves, due to the level of disagreement between 
companies and ERGs.  
TSD 14 does acknowledge some limitations to its own recommendations, with an associated paper 
stating that the model selection algorithm “should not be viewed as a finished product” [34]. The 
limitations include that the AIC/BIC, visual fit and log-cumulative hazard plots only comment on the 
observed follow-up period, and do not necessarily infer on the suitability of the predictive ability of a 
model. These have also been discussed elsewhere [35, 36]. We agree with Bagust and Beale [35] in 
their response to TSD 14, and feel that assessing the visual fit against a KM plot and log cumulative 
hazard plots alone can be challenging as several parametric fits can often appear very similar, 
especially for late observations on the log-time scale. There are few alternative recommendations 
for robust extrapolations,  for example Tremblay et al. (2015) [37] published five criteria for 
transparent extrapolation of survival data, though they are broadly similar to TSD 14. Their fourth 
criterion was to establish uncertainty in the estimate of marginal difference in treatment effects 
using bootstrapping, with high uncertainty indicating low robustness. The fifth criterion was to 
compare the similarity of the observed and extrapolated gains, using a rule of thumb that the ratio 
of relative difference in the extrapolated period divided by the number of months extrapolated 
(post-observed period) should not exceed the ratio of the incremental difference for the observed 
period over the duration of the observed period. These criteria are relatively untested, it is uncertain 
whether they are suitable for discriminating between different parametric models or whether 
following them would recommend a different model to following TSD 14.  
The TSD is critical of using -2 log-likelihood statistic, instead favouring the AIC and BIC both of which 
use this statistic in their calculation. Both AIC and BIC favour a parsimonious model, that is 
considering both the fit to the data and the number of parameters in the model. Whilst such an 
approach should be encouraged when adjusting for confounding effects, it is unclear whether using 
AIC/BIC over -2*log-likelihood statistic leads to a more accurate extrapolation when comparing 
different parametric forms which have similar numbers of parameters. 
 
 We would suggest also comparing a smoothed hazard plot against predicted hazards from the 
parametric models, without necessarily rescaling time on the log scale. This would allow for easier 
identification of deviation from the predicted hazards at the later stages of follow-up, and for easier 
distinction between the parametric curves. This should be done in consideration with the number of 
patients remaining at risk, as late events may incorrectly make a model appear to be a poor fit. 
Another implication is that there is clear potential for companies to implement modern approaches 
into their economic models. Due to lengthy timelines of the appraisal process, it is possible that the 
most recent approaches to extrapolating and capturing uncertainty are unlikely to be seen in a STA. 
There may be resistance to change, with manufacturers perhaps wary of experimenting with new 
techniques when the approval of their intervention is at stake. 
The appraisals in this review all used frequentist methodology to extrapolate survival data and 
explore uncertainty, despite alternative approaches being available. These approaches may fail to 
capture uncertainty or unusual hazard behaviour, and often exclude prior information. Poly- models, 
such as the Poly-Weibull model [38], assume the presence of multiple independent sources of risk 
that operate additively. The Poly-Weibull hazard function emerges as the sum of the independent 
Weibull hazards. Demiris et al found the Poly-Weibull gave a better fit compared to a single Weibull 
model in their examples, however Poly-model fitting can be challenging in the absence of causes of 
event or when the multiple hazards do not appear distinctly within the modelled data [38].  
Negrin et al [39] use Bayesian Model Averaging (BMA) to capture the uncertainty in the 
extrapolation of survival curves, which may be superior to conducting separate PSA and scenario 
analyses with the survival curves. Using BMA to combine the estimates of each parametric fit can 
produce a prediction for mean survival and a credible interval, removing the need to focus on a 
single parametric model. Jackson et al review methods of including external data into survival 
extrapolations [40], which may further improve their accuracy. 
This review highlights the vast uncertainty that remains in many technology assessments, and raises 
the question of whether clinical trials should be designed with greater consideration of the funding 
decision-maker.  
Further research is recommended into when survival data are mature enough to produce reliable 
extrapolations. It is plausible that before a certain length of follow-up and number of events, 
extrapolation is not reliable. This could reduce the need for adjustments to extrapolations, such as 
waning treatment effects, which are often applied when initial extrapolations are implausible but 
introduce additional uncertainty for the company, ERG and appraisal committee. Appraisals 
submitted prior without mature data could be made on a temporary basis, similar to the current 
running of the Cancer Drugs Fund (CDF) in the UK, where the CDF allows patients access to 
interventions, which have demonstrated potential to be cost-effectiveness, but where uncertainty 
remains. 
5 Conclusion 
Cancer STAs use frequentist parametric approaches to extrapolate survival and explore uncertainty. 
Despite adhering to TSD 14, pharmaceutical companies specify parametric curves and other 
assumptions that are routinely rejected by ERGs. More thorough guidance is recommended to 
ensure methods of curve selection are consistent across appraisals. As extrapolations account for 
such a high proportion of an economic model’s time horizon, it is critical that extrapolations are 
supported with strong justification. . Recent developments in Bayesian approaches to extrapolation 
and uncertainty were not implemented. 
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Table 1: Overview of Single Technology Appraisals included in this review. 
ID Intervention Disease 
Time 
Horizon 
Max 
Observed 
follow up 
(months) 
Analysis 
Type 
Used 
Goodnes
s of fit 
statistics 
Assesse
d Visual 
Fit 
Checked 
Plausibilit
y 
Checked 
Consistenc
y with 
external 
data 
Checked 
Consistenc
y between 
OS and PFS 
curves 
Used Log-
cumulativ
e hazard 
plots 
Use
d 
QQ 
plots 
Included 
Survival 
Curve 
Parameters 
in 
probabilisti
c sensitivity 
analysis 
Other 
curves 
explore
d 
ERG 
agreed 
with 
curves 
ERG agreed 
with all 
major 
survival 
assumption
s 
Company 
Preferred 
Parametri
c Fit 
ERG 
Preferred 
Parametric 
Fit 
TA427 
[21] 
Pomalidomide Myeloma 15 years 
29 
Partitione
d Survival 
Model 
Yes Yes Yes No No Yes Yes Yes Yes Yes No 
PFS: Expo 
OS: Gen 
Gamma  
PFS: Expo 
OS: Gen 
Gamma 
TA428 
[10] 
Pembrolizumab 
Non-Small Cell 
Lung Cancer 
20 years 
 
24 
Partitione
d Survival 
Model 
Yes Yes Yes No No Yes No Unclear No Yes No 
PFS: KM + 
Gen 
Gamma 
OS: KM + 
Expo 
PFS: KM + 
Gen 
Gamma 
OS: KM + 
Expo 
TA429 
[19] 
Ibrutinib 
Chronic 
Lymphocytic 
Leukaemia 
20 years 
18 
Markov 
Multistate 
Model 
Yes Yes Yes No No No No Yes Yes No No 
PFS: 
Weibull 
OS: 
Lognormal 
+ Expo 
PFS: Expo 
OS: Expo 
TA432 [9] Everolimus 
Renal Cell 
Carcinoma 
12 years 
19.6 
Partitione
d Survival 
Analysis 
Yes Yes Yes No No No No Unclear Yes 
Unclea
r 
Unclear 
PFS: 
Weibull 
OS: 
Weibull 
Unclear 
TA440 
[32] 
Pegylated 
liposomal 
irinotecan 
hydrochloride 
trihydrate 
(nal iri) 
Pancreatic 
Cancer 
10 years 
36 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Yes Yes No No 
PFS: 
Lognormal 
OS: 
Lognormal 
Preferred 
KM data 
without 
any 
parametri
c fit 
TA446 
[22] 
Brentuximab 
vedotin 
Hodgkin’s 
Lymphoma 
A = 70 
years 
B = 80 
years 
84 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Unclear Yes 
Unclea
r 
Unclear 
PFS: 
Lognormal 
OS: KM + 
Expo 
Unclear 
TA447 
[14] 
Pembrolizumab 
Non-Small Cell 
Lung Cancer 
20 years 
19.7 
Partitione
d Survival 
Model 
Yes Yes Yes No No Yes No Yes No 
Unclea
r 
No 
PFS: KM + 
Weibull 
OS: KM + 
Expo 
Unclear 
TA450 
[18] 
Blinatumomab Leukaemia 50 years 
36 
Partitione
d Survival 
Model 
Yes Yes Yes Yes No No No Yes Yes Yes Yes 
PFS: Gen 
Gamma 
OS: 
Gompertz 
PFS: Gen 
Gamma 
OS: 
Gompertz 
TA451 
[20] 
Ponatinib Leukaemia 100 years 
NR 
Markov 
Multistate 
Model 
Yes Yes Yes No No No No Unclear Yes No No 
PFS: 
Multiple 
OS: 
Multiple 
PFS: 
Multiple 
OS: 
Multiple 
TA457 
[17] 
Carfilzomib  Myeloma 40 years 
53 
Unclear 
Yes Yes Yes Yes No No No Unclear Yes No No 
PFS:  
Weibull 
OS: 
Weibull 
PFS: 
Weibull 
OS: 
Gompertz 
TA458 [8] 
Trastuzumab 
Emtansine 
Breast Cancer 15 years 
27 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Unclear Yes Yes Yes 
PFS:  KM + 
Gamma 
OS: 
Gamma 
PFS: KM + 
Gamma 
OS: 
Gamma 
TA462 
[15] 
Nivolumab 
Hodgkin 
Lymphoma 
40 years 
28 
Unclear 
Yes Yes Yes No Yes No No Unclear Yes Yes No 
PFS:  Expo 
or 
Lognormal 
OS: Expo 
or Weibull 
PFS: Expo 
or 
Lognormal 
OS: Expo 
or Weibull 
TA463 
[11] 
Cabozantinib Kidney Cancer 30 years 
28.7 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Unclear Yes No No 
PFS:  
Loglogistic 
OS: 
Loglogistic 
PFS: 
Loglogistic 
OS: 
Weibull 
TA465 
[28] 
Olaratumab 
Soft Tissue 
Sarcoma 
25 years 
47 
Partitione
d Survival 
Model 
Yes Yes Yes Yes No No No Yes Yes No No 
PFS: KM 
OS: Gen 
Gamma 
PFS: KM 
OS: 
Lognormal 
TA472 
[29] 
Obinutuzumab 
Follicular 
Lymphoma 
25 years 
54 
Company 
chose 
Semi 
Yes Yes Yes No No No No Unclear No No No 
PFS: 
Multiple  
PFS: 
Multiple 
OS: Expo 
Markov 
Model. 
 
ERG 
preferred 
Partitione
d Survival 
Model 
OS: 
Multiple 
TA473 [5] Cetuximab 
Head/Neck 
Cancer 
“lifetime” 
60 
Partitione
d Survival 
Model 
Yes No Yes No No No No Yes Yes No No 
PFS: 
Weibull 
OS: 
Weibull 
PFS: Expo  
OS: KM + 
Expo 
TA476 [6] Paclitaxel 
Pancreatic 
Cancer 
10 years 
45 
Partitione
d Survival 
Model 
Yes Yes Yes No No Yes Yes Unclear Yes No No 
PFS: 
Gamma 
OS: 
Gamma 
PFS: KM + 
Gamma 
OS: KM + 
Gamma 
TA478 
[16] 
Brentuximab 
Vedotin 
Lymphoma 60 years 
82 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Yes Yes No No 
PFS: 
Lognormal 
OS: 
Gamma 
PFS: KM  
OS: KM 
TA483 
[25] 
Nivolumab 
Non-Small Cell 
Lung Cancer 
20 years 
38 
Partitione
d Survival 
Model 
Yes Yes Yes Yes No No No Unclear Yes No No 
PFS: Spline 
OS: 
Loglogistic 
PFS: KM + 
Expo 
OS: KM + 
Expo 
TA484 
[24] 
Nivolumab 
Non-Small Cell 
Lung Cancer 
20 years 
24 
Partitione
d Survival 
Model 
Yes Yes Yes Yes No No No Yes No No No 
PFS: Gen 
Gamma 
OS: Gen 
Gamma 
PFS: KM + 
Expo 
OS: KM + 
Expo 
TA487 
[27] 
Venetoclax Leukaemia 20 years 
24.7 
Partitione
d Survival 
Model 
Yes Yes Yes No No Yes No Yes Yes No No 
PFS: 
Weibull 
OS: 
Weibull 
PFS: ERG 
Weibull 
OS: ERG 
Weibull 
TA488 [7] Regorafenib 
Gastro-
intestinal 
stromal 
tumours 
40 years 
45.9 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Unclear No No No 
PFS: 
Lognormal 
OS: 
Loglogistic 
PFS: 
Lognormal 
OS: 
multiple 
TA489 
[31] 
Vismodegib 
Basal Cell 
Carcinoma 
30 years 
45 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Yes Yes Yes No 
PFS: 
Weibull 
OS: 
multiple 
PFS: 
Weibull 
OS: 
multiple 
TA490 
[26] 
Nivolumab 
Head/Neck 
Cancer 
20 years 
17 
Partitione
d Survival 
Model 
Yes Yes Yes No Yes No No Unclear Yes Yes Yes 
PFS: Gen 
Gamma 
OS: 
Lognormal 
PFS: Gen 
Gamma 
OS: 
Lognormal 
TA491 
[30] 
Ibrutinib 
Walden-
stroms 
macroglobu-
linaemia 
30 years 
30 
Markov 
Multistate 
Model 
Yes Yes Yes No No No No Yes Yes Yes No 
PFS: 
Weibull 
OS: Expo 
PFS: 
Weibull 
OS: Expo 
TA492 
[23] 
Atezolizumab 
Urothelial 
cancer 
20 years 
24.5 
Partitione
d Survival 
Model 
Yes Yes Yes No No No No Unclear Yes No No 
PFS: Gen 
Gamma 
OS: Gen 
Gamma 
PFS: KM + 
Expo  
OS: KM + 
Weibull 
TA495 
[12] 
Palbociclib  Breast Cancer 40 years 
40.5 
Partitione
d Survival 
Model 
Yes No Yes Yes No No No Yes No No No 
PFS: 
Weibull 
OS: 
Weibull 
PFS: KM + 
Expo 
OS: 
Weibull 
TA496 
[13] 
Ribociclib  Breast Cancer 40 years 
34.75 
Markov 
Multistate 
Model 
Yes Yes Yes No No No No Yes Yes No No 
PFS: Expo 
OS: 
Unclear 
PFS: Expo 
OS: 
Unclear 
SUMMARY  
 
 
28 
(100%) 
26 
(93%) 
28 
(100%) 
6 
(21%) 
2 
(7%) 
5  
(18%) 
2  
(7%) 
6 
(21%) 
25 
(89%) 
9 
(32%) 
2  
(7%) 
  
* indicates max follow-up when median was not reported. 
ERG - Evidence Review Group; QQ – Quantile Quantile; Expo – Exponential; KM – Kaplan Meier; OS – Overall Survival; PFS – Progression Free Survival.  
Note: a semi-Markov model’s transition probabilities are dependent on the time spent in a health state. A Partitioned Survival Model estimates the proportion in each health state directly from survival curves using mutually exclusive health 
states. 
 
 
Table 2: Summary of additional findings of this review. 
 Range Mean  Median (IQR) 
Time Horizon (years) 10 to 100  31.4   25 (20, 40) 
Max Observed Follow-up (years) 1.4 to 6.8 3.1 2.9 (2.0, 3.8) 
Proportion of Time Horizon 
Observed using Max 
5.8% to 37.5% 12.4% 10.1% (8.2%, 15.0%) 
Median Observed Follow-up (years) 0.4 to 5.9 2.0 1.3 (1.2, 2.1) 
 Proportion of Time Horizon 
Observed using Median 
2.0% to 11.6% 6.5% 6.7% (4.0%, 8.8%) 
 
 
 
 
 
Figure 1:  PRISMA flow diagram
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